Sector Update: Healthcare Shares Flat Pre-Market; Catalyst Pharmaceutical Partners Rises 14% on Joint Study of Firdapse Tablets

By Staff,

Shutterstock photo

Healthcare stocks:

JNJ: -0.18%

PFE: +0.03%

ABT: flat

MRK: flat

AMGN: flat

Healthcare shares are fairly flat in pre-market trade.

Shares in Catalyst Pharmaceutical Partners ( CPRX ), a specialty pharmaceutical company focused orphan neuromuscular and neurological diseases, are up more than 14% pre-bell after the company announced that a joint study of its Firdapse tablets on cardiac safety met primary endpoints.

The study was jointly funded with, and conducted by BioMarin Pharmaceuticals ( BMRN ). BioMarin is flat pre-market, after closing Tuesday at $68.54.

And, NPS Pharmaceuticals ( NPSP ) said the FDA has accepted and filed for review the company's Biologics License Application (BLA) for Natpara (recombinant human parathyroid hormone 1-84, (rhPTH[1-84])) for the treatment of hypoparathyroidism. Under the Prescription Drug User Fee Act (PDUFA), the goal date for a decision by the FDA is October 24, 2014.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2014 All rights reserved. Unauthorized reproduction is strictly prohibited.

This article appears in: Investing Commodities
Referenced Stocks: BMRN , CPRX , NPSP

More from MT Newswires


MT Newswires

MT Newswires

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by